Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade

Table 1

Characteristics of patients.

Characteristic	Category	All case (%)	Sequencing cases (%)
Age	Median	66 (50-80)	66 (50-77)
Sex	Female	3	0 (0)
	Male	21	9 (100)
Tumor status	T2	17	6
	T3	7	3
Nodal status	Positive	2	0
	Negative	22	9
AJCC stage	II	16	7
	IIIA	8	2
Neoadjuvant chemotherapy	Albumin paclitaxel combined with cisplatin	14	6
	Albumin paclitaxel combined with carboplatin	10	3
Frequency of chemotherapy	2 cycles	19	6
	3 cycles	1	2
	4 cycles	4	1
ORR	CR	2	1
	PR	16	4
	SD	5	4
	PD	1	0